Mesoblast (MESO) Other Accumulated Expenses (2022 - 2025)
Mesoblast recorded quarterly Other Accumulated Expenses of $2.3 million in Q4 2025, up 502.08% quarter-over-quarter from $385000.0 in Q4 2024, and up 502.08% year-over-year from $385000.0 in Q4 2024.
Mesoblast's Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $2.3 million for Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 367,000.00 |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.25 Mn |